Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire • Feb 18, 2026

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025.

GlobeNewsWire • Jan 13, 2026

Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge

Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances.

Seeking Alpha • Dec 31, 2025

What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?

Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 18, 2025

Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know

Sight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Nov 11, 2025

Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript

Sight Sciences, Inc. ( SGHT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Badawi - Co-Founder, President, CEO & Director Jim Rodberg - VP of Finance & Corporate Controller Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Conference Call Participants Hannah Jeffrey - The Gilmartin Group Danielle Antalffy - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Xuesong Wang - Morgan Stanley, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Sight Sciences Third Quarter 2025 Earnings Results Conference Call.

Seeking Alpha • Nov 7, 2025

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth

GlobeNewsWire • Nov 6, 2025

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025.

GlobeNewsWire • Nov 6, 2025

Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 7, 2025

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago.

Zacks Investment Research • Nov 7, 2025